Background and Purpose-Clinical benefit from thrombolysis is reduced as stroke onset to treatment time increases. The use of "mismatch" imaging to identify patients for delayed treatment has face validity and has been used in case series and clinical trials. We undertook a meta-analysis of relevant trials to examine whether present evidence supports delayed thrombolysis among patients selected according to mismatch criteria. Methods-We collated outcome data for patients who were enrolled after 3 hours of stroke onset in thrombolysis trials and had mismatch on pretreatment imaging. We selected the trials on the basis of a systematic search of the Web of Knowledge. We compared favorable outcome, reperfusion and/or recanalization, mortality, and symptomatic intracerebral hemorrhage between the thrombolyzed and nonthrombolyzed groups of patients and the probability of a favorable outcome among patients with successful reperfusion and clinical findings for 3 to 6 versus 6 to 9 hours from poststroke onset. Results are expressed as adjusted odds ratios (a-ORs) with 95% CIs. Heterogeneity was explored by test statistics for clinical heterogeneity, I 2 (inconsistency), and L'Abbé plot. Results-We identified articles describing the DIAS, DIAS II, DEDAS, DEFUSE, and EPITHET trials, giving a total of 502 mismatch patients thrombolyzed beyond 3 hours. The combined a-ORs for favorable outcomes were greater for patients who had successful reperfusion (a-ORϭ5.2; 95% CI, 3 to 9; I 2 ϭ0%). Favorable clinical outcome was not significantly improved by thrombolysis (a-ORϭ1.3; 95% CI, 0.8 to 2.0; I 2 ϭ20.9%). Odds for reperfusion/recanalization were increased among patients who received thrombolytic therapy (a-ORϭ3.0; 95% CI, 1.6 to 5.8; I
vs placebo 1:1; median time for administration of alteplaseϭ3 hours, 59 minutes) confirmed clinical benefit within 4.5 hours of stroke onset. (ORϭ1.34; 95% CI, 1.02 to 1.76; Pϭ0.04). 4 However, the wider 95% CI at 6 hours (0.9 to 1.5 for 271 to 360 minutes in the meta-analysis 4 ) have suggested that there may still be patients able to benefit from thrombolysis even beyond 4.5 hours. Conversely, others may be at increased risk from late treatment. The use of imaging approaches to select patients who have remaining salvageable tissue for delayed treatment has been proposed, most notably approaches that include magnetic resonance imaging (MRI) perfusion/diffusion "mismatch." 5, 6 Several trials have tested thrombolysis in patients selected after MRI; some centers have also incorporated mismatch imaging and delayed thrombolysis into their routine clinical practice. 7 We undertook a meta-analysis of data in the public domain to examine whether extension of the treatment window among patients selected according to the presence of mismatch can be recommended for routine clinical practice.
Methods

Selection of Trials
We planned to include only relevant articles that described the findings of studies that either undertook prospective enrollment of consecutive stroke patients with a mismatch profile suitable for delayed thrombolysis (beyond 3 hours of stroke onset) or had studied mismatch-based, delayed thrombolysis in a randomized controlled design. We excluded case reports, case series, and studies restricted to specific anatomic brain locations. 8 We defined the (1) mismatch profile as a perfusion volume at least 1.2 times that of the infarct core with use of the imaging methodology available at the specific trial center, (2) symptomatic intracerebral hemorrhage (SICH) as a radiologically confirmed cerebral hemorrhage in association with clinical worsening after thrombolytic therapy (within 36 hours in the case of therapy with recombinant tissue-type plasminogen activator [rt-PA] and 72 hours in the case of therapy with desmoteplase), (3) reperfusion and/or recanalization according to the respective studies' definitions, (4) favorable clinical outcome as a National Institutes of Health Stroke Scale (NIHSS) improvement of 8 points from baseline or attainment of an NIHSS score of 0 or 1 and/or a modified Rankin Scale score of 0 or 1, and (5) mortality as death (Rankin Scale score of 6) in the 90 days after thrombolytic therapy. We considered rt-PA and desmoteplase together because both are thrombolytic agents. 9 They differ in some features: desmoteplase lacks the second kringle site in its molecular structure, does not need to be cleaved by plasmin, is active in its single-chain form, has reduced neurotoxicity, and has limited passage through the blood-brain barrier. Desmoteplase has a theoretical advantage over rt-PA because the former is almost nonfunctional when fibrin is absent. 9 -15 Alteplase is already a proven therapy for treating stroke patients within the early hours after stroke onset (NINDS 16 and ECASS III 3 ). 17 Doses that have acceptable safety and efficacy have been identified. 18 -20 Both desmoteplase and alteplase remain investigational for delayed thrombolysis. However, we undertook a sensitivity analyses for any differential effect between desmoteplase and alteplase.
Until the DIAS II study, identification of the ischemic penumbra was based on the mismatch between MRI perfusion-weighted imaging and diffusion-weighted imaging. 18 For the first time, the DIAS II investigators were permitted to select patients on the basis of visual inspection of the mismatch on perfusion computed tomography (CT) images as an alternative to MRI perfusion studies, depending on the local expertise of the imaging center. We included data from either method as reported in the DIAS II publication. 18 We included all trials that defined the mismatch profile as the perfusion volume being 1.2 times the infarct core. We placed no restriction on the manner in which perfusion was measured in these trials. For example, in DIAS II, the mismatch population was identified on the basis of either CT perfusion or MRI perfusion, according to center preference. The determination of mismatch in DEFUSE and EPITHET trials was based on postprocessed perfusion-weighted imaging data that included correction for arterial input and thresholding. In contrast, in the desmoteplase studies, mismatch was determined in "real time," without postprocessing, by the investigator using the "eyeball" technique.
End Points
End points of interest for our meta-analysis were comparisons between thrombolyzed and nonthrombolyzed patients in (1) favorable outcome, (2) reperfusion and/or recanalization, (3) mortality, and (4) SICH. We also examined the rates of favorable versus unfavorable clinical outcome amongst successfully reperfused patients.
Search
We first searched the Web of Knowledge for 10 broad terms: "clinical trial*," "prospective study," "stroke trial*" "thrombolytic agent," "desmoteplase," "tissue plasminogen activator," "recanalization in stroke," " reperfusion therapy in stroke," "penumbra in stroke," and "mismatch hypotheses." Then we refined our search by combining these with terms that underline the mismatch hypotheses and thrombolysis. Our last search was undertaken on March 1, 2009 . From a review of the title and abstract, we selected for further examination all relevant articles describing the original findings of studies that used the mismatch hypotheses and selected patients for thrombolysis despite delay beyond 3 hours of stroke onset. We checked whether any later article or abstract offered supplemental data. Once selected, each article was read completely and the relevant data extracted. We also searched the bibliography of each of these articles for additional articles.
Statistical Analysis
For this meta-analysis, we retrieved "estimate(s) of effect" from the abstract(s). When relevant data were missing, we searched the full text and any supplementary articles. 21 Primarily, we wished to analyze data derived from the patients with a mismatch profile on an intention-to-treat basis, but when intention-to-treat data were unavailable, we accepted "per protocol" data and described the underlying limitations. Our comparisons were mainly planned between patients offered any dose of any thrombolytic agent and the corresponding placebo-treated patients.
We performed subgroup analyses amongst patients who were treated with thrombolytics at doses approved or still under clinical investigation, ie, 90 g/kg desmoteplase or 0.9 mg/kg rt-PA. Comparisons (summary estimates) are expressed as ORs and their 95% CIs. Whereas we applied both fixed (inverse-variance weighting method) and random (adjusted OR [a-OR] 21 ) methods to calculate the summary estimate, we reported only the findings of the fixed method but have indicated the instances where the results diverged. We assessed the heterogeneity with the test statistics for heterogeneity and I 2 for inconsistency supported by examination of L'Abbé plots.
Our analysis included data derived from those patients who were selected (or could have been selected) on the basis of their mismatch profile. To assess whether favorable outcomes (clinical outcomes at day 90) were more common amongst patients who had successful reperfusion, we retrieved data on 242 patients for whom the reperfusion findings were available (the DIAS I trial, Nϭ97 20 ; the DEDAS trial, Nϭ34 19 ; the EPITHET trial, Nϭ77 ["good neurological outcome" for patients with {nϭ30} and without {nϭ47} reperfusion in mismatch patients only] 22 ; and the DEFUSE trial, Nϭ34, in mismatch patients with [nϭ18] and without [nϭ16] early reperfusion 23 ). Corresponding information was not reported in the DIAS II trial. 18 Similarly, to answer whether a favorable clinical outcome occurred more frequently in the thrombolyzed group of patients, information on 410 patients was available (DIAS I, Nϭ102 20 ; DIAS II, Nϭ186 18 ; DEDAS, Nϭ37 19 ; and EPITHET, Nϭ85; mismatch patients with and without good neurological outcome in the thrombolysis group, nϭ42, and the placebo group, nϭ43 22 ) for those patients who received any thrombolytic agent at any dosage. Next, to answer whether reperfusion or recanalization occurred more frequently amongst those who were thrombolyzed, we retrieved data on 211 patients who received thrombolytic therapy at any dose (DIAS I, 97 patients 20 ; DEDAS, intention to treat 37 patients 19 and target population 23 patients; and EPITHET, 77 patients 22 ). To assess mortality between thrombolyzed and nonthrombolyzed patients, we extracted data on 410 patients (DIAS I, 102 patients 20 22 ). Owing to mathematical difficulties involved in calculating OR when the numerator is zero, we combined the DEDAS data with DIAS I data for mortality analysis.
We undertook sensitivity (subgroup) analyses in which we compared the data after excluding the data for those who received doses of desmoteplase that were abandoned for further evaluation. We also analyzed differences in clinical outcome between the patients who were thrombolyzed within 3 to 6 hours of stroke onset versus those who were thrombolyzed beyond 6 hours. Finally, we compared and contrasted the attributes of the studies and assessed their quality on the basis of the manner in which patients were enrolled and the resulting baseline characteristics.
Results
Literature Search
The literature search led to 13 citations on the DEFUSE trial (10 articles) [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , 2 on the DEDAS trial (1 article 19 ), 6 on the DIAS trial 20, 30 , 9 on the EPITHET trial (8 articles 20, 22, [33] [34] [35] [36] , and 2 on DIAS II (1 article). 37 Information on 502 patients was obtained from the 5 main articles describing the relevant trials (DIAS, 104 patients 8 ; DIAS II, 186 patients 18 ; DEDAS, 37 patients 9 ; DEFUSE, 74 patients 10 ; and EPITHET, 101 patients 11 ) , and the data corresponding to patients with a mismatch profile were retrieved for subsequent analysis.
Comparative Analysis of the Mismatch Trials
We compared the attributes that differed between trials to highlight the underlying heterogeneity in the manner in which the selected trials were conducted (Supplemental Table I available online at http://stroke.ahajournals.org). DIAS II 18 enrolled the least severely affected stroke patients (median NIHSS scoreϭ9) and EPITHET, 22 the most severely affected (median NIHSS scoreϭ14 in the treatment arm and 10 in the placebo arm). Median baseline NIHSS scores were 11.5 and 12, respectively, in the DEFUSE 23 and DIAS I 20 trials. We also compared the time since stroke onset until thrombolysis (OTT), and we assessed qualitatively the proportion of patients treated in each trial after 4.5 hours (Supplemental Table II , available online at http://stroke.ahajournals.org). Detailed analysis of OTT could not be undertaken without raw data. 19 (ORϭ0.9; 95% CI, 0.1 to 6.9). The combined data gave a greater adjusted odds for reperfusion/recanalization for the patients who had thrombolytic therapy at any dosage (a-ORϭ3.0; 95% CI, 1.6 to 5.8; PϽ0.05, P for heterogeneityϭ0.26, and I 2 ϭ25.7%; Figure 1a ). We repeated our analysis after excluding desmoteplase doses that were abandoned for clinical development; the subanalysis restricted to 90 g/kg desmoteplase or rt-PA gave an a-ORϭ2.65 and a 95% CI of 1.3 to 5.5 (Pϭ0.007 fixed method; Figure 1b ) and an a-ORϭ2.28 and a 95% CI of 0.7 to 7.3 (Pϭ0.17 random method; Figure 1c ) (P for clinical heterogeneityϭ0.13, and I 2 ϭ50.5%). We also examined the underlying heterogeneity by L'Abbé plot (Figures 2a and 2b) . (DIAS I 20 ORϭ3.4; 95% CI, 1.3 to 8.8; DEDAS 19 ORϭ9.6; 95% CI, 1.5 to 64.6; EPITHET 22 ORϭ7.2; 95% CI, 2.3 to 23.2; and DEFUSE 23 ORϭ5.4; 95% CI, 0.94 to 38.1). For all trials combined, the a-ORs were greater for patients who had successful reperfusion compared with those who did not (a-ORϭ5.2; 95% CI, 3 to 9.1; P for clinical heterogeneityϭ0.60; I 2 ϭ0%; Figure 3a ). In a sensitivity analyses in which DEFUSE 23 trial data were excluded (as DEFUSE, 23 unlike others, was a nonrandomized, prospectively conducted study), the a-OR remained greater among patients with successful reperfusion (a-ORϭ5.2; 95% CI, 2.8 to 9.5; Pϭ0.00; heterogeneity statistics Pϭ0.4; I 2 ϭ0%; Figure 3b ). Figure 4a ). After exclusion of DIAS II data, a-OR was 1.96, 95% CI was 1.06 to 3.63, and for clinical heterogeneity, I 2 was 0% and P was 0.89 ( Figure 4b ).
Findings From Statistical Analyses
Are Favorable Outcomes More Common in Patients Who
Did a Favorable Clinical
We repeated our analysis after excluding desmoteplase doses that were abandoned for clinical development: with 90 g/kg desmoteplase and rt-PA 0.9 mg/kg data alone, we found a-ORϭ1.4; 95% CI, 0.9 to 2.3, Pϭ0.16; for clinical heterogeneity, Pϭ0.56 and I 2 ϭ0%. After exclusion of DIAS II data, ORϭ1.88; 95% CI, 0.95 to 3.72, and heterogeneity 
odds ratio (95% confidence interval) 1 2 5 10 100 
odds ratio (95% confidence interval) 0.2 0.5 1 2 5 10 100
odds ratio (95% confidence interval) 0.1 0.2 0.5 1 2 5 10 100 statistics I 2 ϭ0% and Pϭ0.69 ( Figure 4c ). L'Abbé plots were examined for underlying heterogeneity in these analyses ( Figure 5 ). Under sensitivity analysis, no differential effect of desmoteplase versus alteplase was found, with the ratio of ORϭ0.7 (95% CI, 0.24 to 1.92; Pϭ0.46).
Was There a Greater Probability of Mortality in Thrombolyzed Compared With Nonthrombolyzed Patients?
Here, the individual odds for mortality were nonsignificant in the thrombolysis group: DIAS II 18 ORϭ2.4; 95% CI, 0.7 to 10.1; DIAS I ORϭ3.6; 95% CI, 0.5 to 161.3; EPITHET 22 ORϭ2.7; 95% CI, 0.8 to 10.9; and DEDAS 19 ORϭ0.5; 95% CI, 0.0 to 34.9. The combined data analysis found a significant increase in mortality in the thrombolysis group of patients compared with the placebo group (a-ORϭ2.4; 95% CI, 1.2 to 4.9; Pϭ0.02; P for heterogeneityϭ0.67; and I 2 ϭ0%; Figure 6a ).
Repeating our analysis after excluding data from the abandoned desmoteplase doses, ie, restricting the analysis to patients treated with 90 g/kg desmoteplase or 0.9 mg/kg rt-PA, we found a-ORϭ1.6; 95% CI, 0.7 to 3.7; Pϭ0.28; P for heterogeneityϭ0.56; and I 2 ϭ0% (Figure 6b ). Under sensitivity analysis, no differential effect of desmoteplase versus alteplase was found, with the ORϭ0.8 (95% CI, 0.2 to 3.5; Pϭ0.8).
Was There a Greater Probability of SICH in Thrombolyzed Compared With Nonthrombolyzed Patients?
The individual odds for SICH were nonsignificant: DIAS I ORϭ7.9; 95% CI, 0.7 to infinity; DIAS II ORϭ5.9; 95% CI, 0.5 to infinity; and EPITHET ORϭ152.6; 95% CI, 15.9 to infinity; but the combined odds for SICH were significantly greater for the group that underwent thrombolytic therapy (a-ORϭ24.7; 95% CI, 5.2 to 118.2; heterogeneity statistics I 2 ϭ35.4% and Pϭ0.2; Figure 7a ). After we combined data from DEDAS with DIAS I, the findings remained nonsignificant for the individual odds (DIAS IϩDEDAS ORϭ7.1; 95% CI, 0.7 to infinity) but were significant for the combined analysis (a-ORϭ6.5; 95% CI, 1.2 to 35.4, and for clinical heterogeneity, Pϭ1.0 and I 2 ϭ0%; Figure 7b ). Repeating the analysis by excluding the data associated with abandoned thrombolytic doses, the findings were nonsignificant for both individual odds (DIAS IϩDEDAS ORϭ3.7; 95% CI, 0.03 to infinity; DIAS II ORϭ5.7; 95% CI, 0.2 to infinity; and EPITHET ORϭ6.5; 95% CI, 0.4 to infinity) and in combination a-ORϭ5.4; 95% CI, 0.9 to 31.8; P for heterogeneityϭ0.97; and I 2 ϭ0% (Figure 7c ) but attained marginal significance of the adjusted odds derived by considering the DIAS I and DEDAS data separately (a-ORϭ6.0; 95% CI, 1.00 to 35.8; heterogeneity statistics Pϭ1.00 and I 2 ϭ0%). There were no SICH occurrences in the placebo arms, and therefore, a sensitivity analysis to assess any differential effect of desmoteplase versus alteplase could not be undertaken. 
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DIAS II ORϭ0.8; 95% CI, 0.4 to 1.8; Pϭ0.7). With the data from both trials combined, the a-ORϭ0.9; 95% CI, 0.5 to 1.7, and Pϭ0.8 ( Figure 8 ).
Analysis of Mortality
In DIAS I, 1 placebo and 2 desmoteplase deaths occurred due to cardiac causes. In the DIAS II trial, only 1 of 3 deaths in the 90 g/kg group and 3 of 14 deaths in the 125 g/kg group were considered related to the trial medication. In the DEDAS trial, the sole death in the 90 g/kg group was due to aspiration pneumonia, whereas that in the 125 g/kg groups was due to evolving neurologic deterioration of a left middle cerebral artery infarct, leading to pneumonia.
Discussion
We undertook a meta-analysis of all previous studies that evaluated the principle of physiologic selection for delayed thrombolysis, based on the presence of potentially viable tissue in the ischemic penumbra. 38, 39 These trials used the mismatch hypothesis with either MRI (perfusion/diffusion mismatch) or CT (perfusion/cerebral blood volume mismatch) as a signature of the putative penumbra. 19,20,22,24,25,40 -43 Apart from the recent DIAS II trial, 18 these trials had supported the physiologic basis of the mismatch concept. The disappointing findings of the DIAS II trial have been attributed to limitations of the study and to chance. 37 To test for consistency, we undertook a meta-analysis of the studies that studied the mismatch hypothesis to select and thrombolyze patients despite delays beyond 3 hours. Five trials, DIAS I, 20 DIAS II, 18 EPITHET, 22 DEFUSE, 23 and DEDAS, 19 were available for inclusion. Our results indicate that reperfusion/recanalization is more common with thrombolysis when all doses are considered together, but the significance was lost with the exclusion of data for abandoned doses, which reduced the power of our analysis through effects on sample size. Furthermore, a favorable clinical outcome was more common amongst patients with successful reperfusion of the ischemic parenchyma, despite delays beyond 3 hours from stroke onset. This conclusion was not influenced by inclusion of the nonrandomized DEFUSE trial 23 data. The DIAS II trial 18 did not report reperfusion findings.
However, we did not find evidence that a favorable clinical outcome was significantly improved in the group that underwent thrombolysis. Neither did we find a significant benefit when we excluded doses of desmoteplase that were abandoned for clinical development. The CI around our estimate of effect remains wide and would be consistent with a doubling of odds for a favorable outcome, although in this respect, DIAS II suggests that the likely upper limit may be 1.6. Even so, odds of 1.6 remain greater than those achieved in unselected patients treated with rt-PA in the ECASS III trial 3 and have been regarded as sufficient to influence national and European stroke treatment guidelines (SIGN 44 and ESO 45 ).
Late treatment, even amongst selected patients, may carry some risk. We found a marginally significant increase in the odds of death among all treated patients, with a point estimate of 2.4. When we restricted the analysis to 0.9 mg/kg rt-PA and to the dose of desmoteplase that remains under development (90 g/kg), the OR for mortality fell to 1.6 and the risk was nonsignificant. Higher doses of desmoteplase were clearly linked to excessive SICH and were abandoned for this reason. Our analysis did not take into account the attributed cause of death. Many deaths in DIAS II and EPITHET were considered unrelated to treatment. The attribution may be important for understanding the mechanism of effect, but caution is required when drawing conclusions from subjective assessments such as these. Treatment failure can contribute to late death, just as unrecognized excitotoxic damage may represent a potential mechanism. Regardless, if mortality is increased, this may be mediated via hemorrhagic transformation.
Despite a lack of significance in the individual odds for SICH in patients given thrombolytic therapy, the a-OR indicated a statistically significant increase in SICH after delayed thrombolysis. Similarly, an increased risk of SICH has long been recognized for time-based t-PA in the established clinical windows, but this is offset by the improved clinical outcomes in treated patients. After exclusion of doses of desmoteplase that were abandoned for clinical development, 20 the adjusted odds for SICH again lost significance.
Caution is required in interpreting these post hoc subgroup analyses. Although the inclusion of data from all doses may give a falsely pessimistic view of the risk/benefit profile after mismatch-based thrombolysis, post hoc exclusion of doses that were abandoned in clinical development is a data-driven decision and raises statistical concerns of bias that can only be assuaged by further prospective trials. We found no evidence that relatively earlier (3-to 6-hour) versus later (6-to 9-hour) treatment influenced our findings. This is particularly relevant, because ECASS III has recently shown that unselected patients benefit from alteplase given within 4.5 hours of stroke onset, and a small proportion of patients in the mismatch trials would now be considered eligible for such treatment. We cannot exclude the possibility that some of the potential benefit among mismatch patients may be time dependent, but it appears unlikely that this is sufficient to explain all effects. Now that the ECASS III results have been presented, another meta-analysis of individual patient data from the trials studied herein should be undertaken to assess clinical and radiologic outcomes for patients who were thrombolyzed beyond 4.5 hours of stroke onset. Similarly, an additional analysis comparing outcomes in patients with mismatch versus those without mismatch is desirable but was beyond the scope of our meta-analysis.
Our meta-analysis included data from 5 different trials, 18 -20,22-23 of which DEFUSE 23 could be considered only in the analysis of a favorable clinical outcome among patients with reperfusion versus no reperfusion. DIAS II 18 did not report reperfusion findings and had to be excluded where these data were needed. The L'Abbé plot 46, 47 suggested that DIAS II 18 contributed to the heterogeneity in the combined analysis of favorable outcomes in all thrombolyzed patients, and the DEDAS trial contributed to the heterogeneity in the analysis of reperfusion and recanalization in patients thrombolyzed with the abandoned doses excluded. Both sources of heterogeneity appeared to affect the results by virtue of the effects of sample size on the power of a study.
We know that the number needed to treat to achieve an enhanced favorable outcome with alteplase may be as few as 7 within 3 hours, but this number has risen by 3 to 4.5 hours to Ϸ14. 3 When treatment with alteplase is started within 6 hours OTT, the number needed to treat rises to 25. 48 Hence, our challenge is to identify those patients most likely to benefit from delayed thrombolysis. The use of either MRI to identify perfusion/diffusion mismatch or a CT-based alternative is attractive. It is clear from our data that delayed thrombolysis among patients selected according to mismatch imaging is associated with increased reperfusion/recanalization and that recanalization/reperfusion is associated with improved outcomes. At present, although the data remain consistent with improved functional outcome from delayed thrombolysis among mismatch patients, a statistically significant benefit on functional outcomes has not been confirmed. Although our pooled results suggest that mortality may be higher, the retention of excessive doses of desmoteplase in the analysis is likely to lead to overestimation of any risk.
We note that existing methods for defining mismatch may be optimized in the future, resulting in greater power of the mismatch-based thrombolysis studies. For example, we considered 1.2 as the cutoff for defining a mismatch profile. However, a post hoc analysis of the DEFUSE study has recently shown that the highest sensitivity and specificity occurred at a mismatch ratio of 2.6, suggesting that the previous studies were probably underpowered and lacked a sufficiently rigorous definition for the mismatch ratio. 27 Furthermore, the 2-second threshold for Tmax is likely also suboptimal, as a posthoc analyses of DEFUSE data showed a significantly better correlation between infarct growth and penumbra salvage volume for perfusion-weighted imaging lesions defined by Tmax Ͼ6 seconds. 29 The EPITHET investigators reported similar findings. 33 It is now clear that both trials included significant volumes of benign oligemia in their mismatch assessments. Recently, automated online anal-ysis of MR mismatch has been described that facilitates rapid selection of patients for delayed treatment. In summary, continued refinement in the definitions of different perfusion parameters may result in a better choice of the best measure of perfusion (Tmax, time to peak, mean transit time, cerebral blood volume, or cerebral blood flow) and correction for arterial input functions.
Thus, the definitions used in the trials published to date have been generous and have included many patients who had limited penumbral tissue and limited prospects of clinical improvement in response to thrombolysis. The recently formed STIR collaboration is initiating a detailed examination of this topic. The diversity of mismatch definitions and large number of investigators involved in these studies weaken conclusions about the potential value of mismatch in the future clinical management of patients with stroke. However, these weaknesses do not extend to our conclusions about the status of existing evidence for use of thrombolysis among mismatch patients: patients were selected according to the best intentions of the investigators under protocols that were state of the art when written, although they have already been superseded. Prospective phase III trials are required to test whether thrombolysis is associated with a favorable risk/benefit ratio when used under modified circumstances. In Australia, the EXTEND trial, which will use a phase III design and randomization of patients 4.5 to 9 hours after stroke onset to alteplase or placebo and automated mismatch selection, will test this hypothesis. Meanwhile, although the concept of selection of patients based on individual pathophysiology rather than a rigid time window remains attractive, delayed treatment according to mismatch selection cannot be recommended as part of routine care until or unless further trials show benefit. Disclosures N.K.M. is supported by a University of Glasgow scholarship. G.W.A. was the principal investigator of the DEFUSE trial, is a consultant to Genentech and to Lundbeck, and was cochair for the steering committee for DIAS I-IV. S.M.D. was coprincipal investigator of the EPITHET trial, is on the advisory board of Servier Australia, and has received honoraria from Boehringer Ingelheim for lectures. G.A.D. was coprincipal investigator of the EPITHET trial, is a member of advisory boards for Servier Australia and Boehringer Ingelheim, and has received honoraria from both companies. A.J.F. is a consultant to Paion and to Forest Laboratories. W.H. was chairman of the steering committee of DIAS and cochair of the steering committees of DEDAS and DIAS II trials, sponsored by Paion and Forest, and received honoraria for his activities in the conduct and development of the trial. K.R.L. was chairman of the data monitoring committees for DIAS I-IV, DEDAS, and ECASS III trials of thrombolysis in acute ischemic stroke, sponsored by Paion, Forest Laboratories, Lundbeck, and Boehringer Ingelheim. 
二者在某些方面仍有不同 ：去氨普酶的分子结构中 缺乏第二个环状结构，不需要被纤溶酶断开，它在 单环结构时具有生物活性，神经毒性较 rt-PA 降低且 只有有限的数量能通过血脑屏障。理论上去氨普酶 比 rt-PA 具有优越性，因为在没有纤维蛋白的情况下 去氨普酶几乎没有生物学活性 [9] [10] [11] [12] [13] [14] [15] 。但阿替普酶是已 经经过临床试验证实在卒中早期使用有效的溶栓药 物 (NINDS [16] 和 ECASS III [3] ) [17] 。其可接受的安全和 有效剂量也已经被证实 [18] [19] [20] 。但是对于扩大溶栓时 间窗后的有效性来说，二者尚需要进一步的研究证 明。不过，我们还对所有关于去氨普酶与阿替普酶 疗效差异的研究进行了敏感度分析。 在 DIAS II 研究之前，所有对缺血半暗带的识 别都是通过磁共振灌注加权成像与弥散加权成像之间 的错配来实现 [18] 。而
文献检索
首 先， 我 们 在 Web of Knowledge 网 站 上 以 "clinical trial" 、 "prospective study" 、 "stroke trail*" 、 "thrombolytic agent" 、 "desmoteplase" 、 "tissue plasminogen activator" 、 "recanalization in stroke" 、 "reperfusion therapy in stroke" ， "penumbra in stroke" 和 "mismatch hypothesis"10 个广义词条进行检索。然 后， 对这些文献进行精确定义， 提炼出以"错配假说" [20] ；DIAS II 中 N=186 [18] ； DEDAS 中 N=37 [19] 以及 EPITHET 中 N=85 ；在溶栓 治疗组中，存在错配且伴有或不伴有良好临床结局 的患者数 N=42，而在安慰剂组 N=43 [22] )。接下来， 为了回答是否接受溶栓治疗的患者更容易发生再灌 注或血管再通，我们追溯了 211 例以任何溶栓药物 剂量接受溶栓治疗的患者 ( 其中 DIAS I 中 97 例 [20] ； DEDAS 中意向治疗的患者数为 37 例 [19] ，而最终的 目标人群患者数则为 23 例 ；在 EPITHET 中 77 例 [22] )。 为了评估溶栓组与未溶栓组患者死亡率的差异，我们 提取了 410 例患者的信息 ( 其中 DIAS I 中 102 例 [20] ； DIAS II 中 186 例 [18] ；DEDAS 中 37 例 [19] 以及 EPI-THET 中 85 例存在错配的患者 [22] )。为了评估溶栓
章 [20, 22, [33] [34] [35] [36] 
EPITHET，101 名患者 [22] )，同时还提取了与错配模 型相关的数据以进行后续分析。 错配模型试验的比较分析 我们比较了各项试验的不同属性，强调入选的 这些试验在实施方法方面存在潜在的异质性 ( 补充 表 I， 来 自 网 页 http://stroke.ahajournals.org)。DIAS II [18] 入选人群为受累最轻的卒中患者 (NIHSS 得分中 位数 =9)，而 EPITHET [22] 入选人群为严重受累的卒 中患者 (NIHSS 得分中位数在治疗组 =14，安慰剂组 =10)。DEFUSE [23] 和 DIAS I [20] 基线的 NIHSS 评分的 [19] (OR=0.9 ；95% CI，0.1-6.9) 中， 此优势却并不明显。联合分析数据显示接受任一剂 量溶栓治疗的患者有更高的再灌注 / 血管再通的校 正优势 (a-OR=3.0 ；95% CI，1.6-5. [20] OR=3.4 ； 95% CI， 1.3-8.8； DEDAS [19] OR=9.6； 95% CI， 1.5-64.6；
EPITHET [22] OR=7.2 ；95% CI，2.3-23.2 ；DEFUSE [23] OR=5.4 ；95% CI，0.94-38.
溶栓组患者相比发生良好临床结局的优势并不显 著 ：DIAS I [20] OR=2.2 ；95% CI，0.7-7.4 ；DEDAS [19] OR=2.4 ；95% CI，0.4-28.0 ；EPITHET [22] OR=1.7 ； 95% CI，0.7-4.4； DIAS II [18] OR=0.8； 95% CI，0.4- 和 DIAS II 均未提示有显著的试验个体优势 (DIAS I OR=1.07 ； 95% CI，0.4-2.9 ； P=0.9 ； DIAS II OR= 0.8 ； 95% CI，0.4-1.8 ；P=0.7)。二者数据联合分析得出调 整 OR=0.9 ；95% CI，0.5-1.7 ；P=0.8( 见图 8)。 死亡率分析 在 DIAS I 试验中，安慰剂组 1 例及去氨普酶组 2 例均死于心脏疾病。在 DIAS II 中，90 μg/kg 组中，3 例死亡，125 μg/kg 组中 14 例死亡，其中 90 μg/kg 组中 1 例和 125 μg/kg 组中 3 例死亡认为与试验药物有关。 在 DEDAS 试验中，90 μg/kg 组唯一的 1 例死亡归因 于吸入性肺炎，而 125 μg/kg 组中的死亡归因于左侧 大脑中动脉梗死使神经功能恶化，导致肺炎发生。 讨论 依据缺血半暗带内存在潜在可挽救的脑组织的 理论，我们对既往进行的评估扩大时间窗的生理学 选择策略的研究进行了荟萃分析 [38, 39] 。这些研究均 采用了错配假说，主要通过磁共振 ( 灌注 / 弥散错 配 ) 或 CT( 灌注 / 脑血容量错配 ) 检查手段来显示假 设存在的缺血半暗带 [19, 20, 22, 24, 25, [40] [41] [42] [43] 。除了最近发表 的 DIAS II 试验 [18] 之外，所有相关的试验均支持错 配概念存在生理学基础。DIAS II 试验令人失望的结 果主要归结于研究设计的局限性以及偶然机遇 [37] 。 为了验证结果的一致性，我们对采用错配模型来筛 选患者进行溶栓 ( 尽管超过了 3 小时时间窗 ) 治疗 的所有研究进行了荟萃分析。入选的试验共 5 个 ： DIAS I [20] ，DIAS II [18] ，EPITHET [22] ，DEFUSE [23] 以 及 DEDAS [19] 。荟萃分析结果表明，如果将所有数据 联合起来分析，溶栓患者发生再灌注 / 血管再通的 可能性要大于未溶栓患者，但是如果将已经剔除剂 量的数据排除在外，上述差异则无显著统计学意义， 这主要是因为剔除剂量的数据通过样本量的作用形 式降低了统计的把握度。此外，尽管在超过 3 小时 时间窗后实施扩大时间窗溶栓治疗，成功实现缺血 半暗带再灌注的患者其发生良好临床结局的可能性 要显著高于未实现再灌注的患者。这一结论并不受非 随机的 DEFUSE 试验数据 [23] 的影响。而 DIAS II [18] 试验在再灌注方面未发现上述差异。 但是，在溶栓治疗组中，我们并没有发现其临 床结局显著优于对照组的证据，同样也未发现在排 除去氨普酶试验中放弃了进行下一步研究的剂量组 之后，溶栓组较对照组有显著获益。我们荟萃分析得 出的效应估计的可信区间过宽， 欲得到良好临床结局， 其比值比就需要加倍才行，即使这样，DIAS II 试验 表明其可信区间的可能上限值仅为 1.6。即使是 1.6 这样的比值比，也要大于在 ECASS III 中未经筛选即 给予 rt-PA 治疗患者的比值比。这足以影响英国国家 以及欧洲卒中治疗指南 (SIGN [44] 和 ESO [45] ) 
